Ann: Continued promising results in PTX-100 TCL trial, page-33

Under normal condition, with the recent FDA approval and today's announcement, PTX won't be trading under 20 cents for sure. Might even have hit 30 cents already.

It is not so simple to make comparison between PTX and IMU based on how many complete responses and so forth. Each have their own reasons for being. There are a lot of moving parts to consider.

IMU is where it is probably due to the potential of its CF33 virus being able to obliterate solid tumor. And that is 90% of the total cancer market which is basically still untapped. And by all accounts, its CF33 is working like it should as seen in the animal models.

I hold both and I believe both have enormous potential. Either one that goes kaboom first, I am fine with it